Search
Cediranib
go.drugbank.com/drugs/DB04849InvestigationalIt is being developed clinically as a once-daily oral therapy for the treatment of cancer. … The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro.
Isatin
go.drugbank.com/drugs/DB02095ExperimentalIsatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids. … The compound is found in many plants and Schiff bases of Isatin are have been investigated for pharmaceutical applications.
TAS-102
go.drugbank.com/drugs/DB08937InvestigationalTAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. … It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis.
Ganulameran
go.drugbank.com/drugs/DB16442InvestigationalAs such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.
5-Methoxy-N,N-diisopropyltryptamine
go.drugbank.com/drugs/DB01441ExperimentalIllicitThis substance is abused for its hallucinogenic effects. … 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine,
CTT-1057
go.drugbank.com/drugs/DB14965InvestigationalCTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).
Socazolimab
go.drugbank.com/drugs/DB18845InvestigationalSocazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).
Zilovertamab vedotin
go.drugbank.com/drugs/DB18457InvestigationalZilovertamab vedotin is an Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (
Fluindione
go.drugbank.com/drugs/DB13136ApprovedWithdrawnFluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.
Xamoterol
go.drugbank.com/drugs/DB13781ApprovedXamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients.